Biogen Idec, Inc. (BIIB) Tops Q3 EPS Views; Boosts FY13 Outlook
Tweet Send to a Friend
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q3 EPS of $2.35, $0.25 better than the analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
